Anti-BCMA CAR T-cell Therapy Reins in Myeloma
- PMID: 31164342
- DOI: 10.1158/2159-8290.CD-NB2019-063
Anti-BCMA CAR T-cell Therapy Reins in Myeloma
Abstract
Autologous immune cells genetically engineered to target B-cell maturation antigen can help patients with relapsed or refractory multiple myeloma achieve deep molecular remissions with minimal neurotoxicity, according to initial data from a phase I trial.
©2019 American Association for Cancer Research.
Comment on
-
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226. N Engl J Med. 2019. PMID: 31042825 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials